NASDAQ:VKTX Viking Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Viking Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.03 -0.06 (-0.99 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$5.94Now: $6.03▼$6.0950-Day Range$5.73MA: $6.92▼$8.1152-Week Range$3.26Now: $6.03▼$8.87Volume1.20 million shsAverage Volume1.43 million shsMarket Capitalization$438.73 millionP/E RatioN/ADividend YieldN/ABeta2 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingViking Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.33, Viking Therapeutics has a forecasted upside of 170.9% from its current price of $6.03.Amount of Analyst CoverageViking Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.5 Community Rank Outperform VotesViking Therapeutics has received 545 “outperform” votes. (Add your “outperform” vote.)Underperform VotesViking Therapeutics has received 230 “underperform” votes. (Add your “underperform” vote.)Community SentimentViking Therapeutics has received 70.32% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote “Outperform” if you believe VKTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldViking Therapeutics does not currently pay a dividend.Dividend GrowthViking Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viking Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,422,968.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of Viking Therapeutics is held by insiders.Percentage Held by Institutions55.30% of the stock of Viking Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Viking Therapeutics are expected to decrease in the coming year, from ($0.61) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viking Therapeutics is -13.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viking Therapeutics is -13.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViking Therapeutics has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.80 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VKTX Previous Symbol CUSIPN/A CIK1607678 Webwww.vikingtherapeutics.com Phone858-704-4660Debt Debt-to-Equity RatioN/A Current Ratio29.89 Quick Ratio29.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.83 per share Price / Book1.57Profitability EPS (Most Recent Fiscal Year)($0.36) Net Income$-25,780,000.00 Net MarginsN/A Return on Equity-11.90% Return on Assets-11.56%Miscellaneous Employees17 Outstanding Shares72,758,000Market Cap$438.73 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $6.03 -0.06 (-0.99 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VKTX News and Ratings via Email Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions How has Viking Therapeutics' stock price been impacted by Coronavirus (COVID-19)? Viking Therapeutics' stock was trading at $5.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VKTX shares have increased by 18.9% and is now trading at $6.03. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Viking Therapeutics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Viking Therapeutics. When is Viking Therapeutics' next earnings date? Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Viking Therapeutics. How were Viking Therapeutics' earnings last quarter? Viking Therapeutics Inc (NASDAQ:VKTX) announced its quarterly earnings data on Wednesday, July, 29th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.01. View Viking Therapeutics' earnings history. What price target have analysts set for VKTX? 11 equities research analysts have issued 12 month price objectives for Viking Therapeutics' stock. Their forecasts range from $12.00 to $25.00. On average, they expect Viking Therapeutics' share price to reach $16.33 in the next year. This suggests a possible upside of 170.9% from the stock's current price. View analysts' price targets for Viking Therapeutics. Are investors shorting Viking Therapeutics? Viking Therapeutics saw a decrease in short interest during the month of August. As of August 14th, there was short interest totaling 8,730,000 shares, a decrease of 17.6% from the July 30th total of 10,590,000 shares. Based on an average daily trading volume, of 1,340,000 shares, the short-interest ratio is currently 6.5 days. Approximately 12.3% of the shares of the company are sold short. View Viking Therapeutics' Short Interest. Who are some of Viking Therapeutics' key competitors? Some companies that are related to Viking Therapeutics include Eidos Therapeutics (EIDX), Prestige Consumer Healthcare (PBH), Revance Therapeutics (RVNC), Kura Oncology (KURA), Uniqure (QURE), Cytokinetics (CYTK), Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), ALX Oncology (ALXO), ZEALAND PHARMA/S (ZEAL), Generation Bio (GBIO), Dicerna Pharmaceuticals (DRNA) and MacroGenics (MGNX). View all competitors. What other stocks do shareholders of Viking Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Verastem (VSTM), Advanced Micro Devices (AMD), Energy Transfer LP Unit (ET) and Inovio Pharmaceuticals (INO). Who are Viking Therapeutics' key executives? Viking Therapeutics' management team includes the following people: Dr. Brian Lian, Pres, CEO & Director (Age 54, Pay $735k)Mr. Gregory S. Zante, Sr. VP of Fin. (Age 49)Mr. Michael Morneau, VP of Fin. & Admin. (Age 55)Ms. Amy Broidrick, Sr. VP of Corp. Devel.Ms. Marianne Mancini, Sr. VP of Clinical Operations When did Viking Therapeutics IPO? (VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager. What is Viking Therapeutics' stock symbol? Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX." Who are Viking Therapeutics' major shareholders? Viking Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (11.63%), Vanguard Group Inc. (4.66%), FMR LLC (2.61%), Goldman Sachs Group Inc. (0.79%), Raymond James & Associates (0.52%) and State of Wisconsin Investment Board (0.52%). Company insiders that own Viking Therapeutics stock include Ligand Pharmaceuticals Inc and Matthew W Foehr. View institutional ownership trends for Viking Therapeutics. Which major investors are selling Viking Therapeutics stock? VKTX stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, FMR LLC, SG Americas Securities LLC, Bailard Inc., UBS Group AG, Alps Advisors Inc., Creative Planning, and Exane Derivatives. Company insiders that have sold Viking Therapeutics company stock in the last year include Ligand Pharmaceuticals Inc, and Matthew W Foehr. View insider buying and selling activity for Viking Therapeutics. Which major investors are buying Viking Therapeutics stock? VKTX stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Raymond James & Associates, WINTON GROUP Ltd, Two Sigma Advisers LP, Raymond James Financial Services Advisors Inc., Rafferty Asset Management LLC, Vanguard Group Inc., and Swiss National Bank. View insider buying and selling activity for Viking Therapeutics. How do I buy shares of Viking Therapeutics? Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Viking Therapeutics' stock price today? One share of VKTX stock can currently be purchased for approximately $6.03. How big of a company is Viking Therapeutics? Viking Therapeutics has a market capitalization of $438.73 million. The biotechnology company earns $-25,780,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Viking Therapeutics employs 17 workers across the globe. What is Viking Therapeutics' official website? The official website for Viking Therapeutics is www.vikingtherapeutics.com. How can I contact Viking Therapeutics? Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
